Literature DB >> 19560101

Markers of Alzheimer's disease in a population attending a memory clinic.

Giovanni B Frisoni1, Annapaola Prestia, Orazio Zanetti, Samantha Galluzzi, Melissa Romano, Maria Cotelli, Massimo Gennarelli, Giuliano Binetti, Luisella Bocchio, Barbara Paghera, Giovanni Amicucci, Matteo Bonetti, Luisa Benussi, Roberta Ghidoni, Cristina Geroldi.   

Abstract

BACKGROUND: New marker-based criteria for the diagnosis of Alzheimer's disease (AD) were recently proposed. We describe their operational translation in 144 consecutive patients referred to our Memory Clinic.
METHODS: Visual ratings of hippocampal atrophy and of cortical glucose hypometabolism in magnetic resonance imaging and positron emission tomography, and concentrations of total tau and Abeta1-42 in cerebrospinal fluid were assessed in 12 patients with subjective memory complaints (SMCs) (Mini-Mental State Examination [MMSE] score, 28.0 +/- 1.1 [mean +/- SD]), 37 with mild cognitive impairment (MCI) (MMSE, 25.1 +/- 3.6), 55 with AD (MMSE, 21.1 +/- 3.5), and 40 with non-AD dementia (MMSE, 21.6 +/- 5.5).
RESULTS: The sensitivity for AD of each individual biomarker was higher (65% to 87%) than for MCI (18% to 50%). Each biomarker's specificity for SMC and non-AD dementias was good to moderate (83% and 53%). Positivity for at least one marker increased the probability 38 times of belonging to the AD group (P < 0.0001).
CONCLUSION: The new diagnostic criteria can be operationalized in clinical routines, but longitudinal studies of MCI patients will need to assess the criteria's prognostic value.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19560101     DOI: 10.1016/j.jalz.2009.04.1235

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  29 in total

1.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

Authors:  Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

2.  Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis.

Authors:  Scott C Neu; Judy Pa; Walter Kukull; Duane Beekly; Amanda Kuzma; Prabhakaran Gangadharan; Li-San Wang; Klaus Romero; Stephen P Arneric; Alberto Redolfi; Daniele Orlandi; Giovanni B Frisoni; Rhoda Au; Sherral Devine; Sanford Auerbach; Ana Espinosa; Mercè Boada; Agustín Ruiz; Sterling C Johnson; Rebecca Koscik; Jiun-Jie Wang; Wen-Chuin Hsu; Yao-Liang Chen; Arthur W Toga
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

3.  PSACNN: Pulse sequence adaptive fast whole brain segmentation.

Authors:  Amod Jog; Andrew Hoopes; Douglas N Greve; Koen Van Leemput; Bruce Fischl
Journal:  Neuroimage       Date:  2019-05-24       Impact factor: 6.556

4.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

Authors:  Stephanie J B Vos; Frans Verhey; Lutz Frölich; Johannes Kornhuber; Jens Wiltfang; Wolfgang Maier; Oliver Peters; Eckart Rüther; Flavio Nobili; Silvia Morbelli; Giovanni B Frisoni; Alexander Drzezga; Mira Didic; Bart N M van Berckel; Andrew Simmons; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Simon Lovestone; Cristina Muscio; Sanna-Kaisa Herukka; Eric Salmon; Christine Bastin; Anders Wallin; Arto Nordlund; Alexandre de Mendonça; Dina Silva; Isabel Santana; Raquel Lemos; Sebastiaan Engelborghs; Stefan Van der Mussele; Yvonne Freund-Levi; Åsa K Wallin; Harald Hampel; Wiesje van der Flier; Philip Scheltens; Pieter Jelle Visser
Journal:  Brain       Date:  2015-02-17       Impact factor: 13.501

Review 5.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Harald Hampel; Michael Weiner; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

6.  Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design.

Authors:  R S Doody
Journal:  J Nutr Health Aging       Date:  2010-04       Impact factor: 4.075

7.  Supporting evidence for using biomarkers in the diagnosis of MCI due to AD.

Authors:  Samantha Galluzzi; Cristina Geroldi; Giovanni Amicucci; Luisella Bocchio-Chiavetto; Matteo Bonetti; Cristian Bonvicini; Maria Cotelli; Roberta Ghidoni; Barbara Paghera; Orazio Zanetti; Giovanni B Frisoni
Journal:  J Neurol       Date:  2012-10-16       Impact factor: 4.849

8.  Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series.

Authors:  Annapaola Prestia; Anna Caroli; Karl Herholz; Eric Reiman; Kewei Chen; William J Jagust; Giovanni B Frisoni
Journal:  Alzheimers Dement       Date:  2013-01-30       Impact factor: 21.566

Review 9.  The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2014-02-01

10.  The A/T/N model applied through imaging biomarkers in a memory clinic.

Authors:  Alessandra Dodich; Aline Mendes; Frédéric Assal; Christian Chicherio; Barinjaka Rakotomiaramanana; Paulina Andryszak; Cristina Festari; Federica Ribaldi; Max Scheffler; Roger Schibli; Adam J Schwarz; Dina Zekry; Karl-Olof Lövblad; Marina Boccardi; Paul G Unschuld; Gabriel Gold; Giovanni B Frisoni; Valentina Garibotto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.